submit to the journals

Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions

US Neurology. 2018;14(Suppl. 1):2–7


Over half of patients with Parkinson’s disease (PD) will develop psychosis during the course of their disease. Characterized by hallucinations and delusions, Parkinson’s disease psychosis (PDP) is clinically distinct from other psychotic disorders. Despite the high prevalence of PDP in patients with PD, patients often under-report symptoms of hallucinations and delusions, potentially due to embarrassment or perceived stigma. It is necessary for physicians to discuss with patients with PD the symptoms of PDP. Parkinson’s disease psychosis can begin with the patients retaining insight into their symptoms – e.g., that their hallucinations are not real – yet, as PDP progresses, insight is often lost and symptoms worsen. The atypical antipsychotic pimavanserin is the first and only US Food and Drug Administration-approved treatment for hallucinations and delusions associated with PDP. The mechanism of action of pimavanserin is unknown but is thought to be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors. Parkinson’s disease psychosis is thought to result from overactivation of serotonergic signaling in several regions of the brain, including the ventral visual pathway. Clinical trials have demonstrated that pimavanserin 34 mg once daily reduces hallucinations and delusions in patients with PDP without impairing motor function.
Keywords: Parkinson’s disease psychosis (PDP), hallucinations, delusions, pimavanserin, diagnosis, treatment
Disclosure: Catherine Amey was an employee of Touch Medical Media. Stuart Isaacson has received honoraria for CME, consultancy, research grants, and/or promotional speaking on behalf of: AbbVie, ACADIA, Acorda, Adamas, Addex, Allergan, Amarantus, Axovant, AZ Therapies, Biogen, Britannia, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Michael J Fox Foundation, Neurocrine, NeuroDerm, Parkinson Study Group, Pfizer, Pharma2B, Prexton, Roche, Sanofi, Shire, Sunovion, Teva, UCB, US WorldMeds, and Zambon. Daniel Kremens has worked as a consultant for ACADIA, Teva, GE Healthcare, US WorldMeds, Impax, UCB, Kyowa, Acorda, Sunovion, St. Jude Medical, Adamas, Neurocrine and Prexton Therapeutics; received speaker’s honoraria for ACADIA, Teva, US WorldMeds, Impax, and UCB; and received research funding from Civitas and Enterin.
Review Process: This article reports the proceedings of an Industry Therapeutic Update held at the 69th Annual American Academy of Neurology (AAN) Meeting (April 22–28, 2017) in Boston, MA, USA, and as such, has not been subject to this journal’s usual peer-review process. The report was reviewed for scientific accuracy by the therapeutic update speakers and an editorial board member before publication.
Compliance with Ethics: Written informed consent was not obtained from the patient case included in this report; Maria is a fictional name and no identifying information or images have been used.
Acknowledgments: Writing assistance was provided by Catherine Amey and Stuart Wakelin, Touch Medical Media, and funded by ACADIA Pharmaceuticals Inc. Editorial review was provided by Mary Selle and Julia Day from the Arbor Scientia Group.
Authorship: All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.
Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. © The Authors 2018.

Received: February 20, 2018 Published Online: March 26, 2018
Correspondence: Catherine Amey, Touch Medical Media, The White House, Mill Road, Goring-On-Thames, RG8 9DD, UK. E:
Support: The publication of this article was supported by ACADIA Pharmaceuticals Inc. The views and opinions expressed in the article are those of the authors.

Pathologically, Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies.1 In a staging model proposed by Braak in 2003,2 the presence of midbrain lesions are preceded by degeneration and Lewy bodies in lower brain stem nuclei. Indeed, non-motor features such as constipation, sleep disorders, hyposmia, and depression may precede motor symptoms by years and even decades (Figure 1).3 Throughout the course of PD, it has become increasingly recognized that non-motor symptoms continue to occur as motor symptoms progress.3

Of the one million people in the US who live with PD,4 more than 50% will develop psychosis during the course of their disease.5 Parkinson’s disease psychosis (PDP) is clinically distinct from other psychotic disorders such as schizophrenia, and is characterized by hallucinations6–8 and delusions.6–9 Visual hallucinations – including presence or passage hallucinations – or illusions are most common. It is common for patients to report seeing animals or children (see case study). Tactile hallucinations may accompany visual hallucinations; other types include auditory (e.g., music, indistinct voices), olfactory, somatic and gustatory hallucinations.6–8 Delusions frequently include beliefs of marital infidelity and relatives stealing money.7,9–11


Presentation and medical history

  • Maria is 74 years old and was diagnosed with PD 7 years ago.
  • She also has osteoporosis, although she has not received treatment for it.
  • Maria has been taking carbidopa/levodopa for 5 years, and although in the past this managed her motor symptoms fairly well, over the past year her motor symptoms have worsened.
  • She recently fell and broke her wrist, and as a result Maria’s carbidopa/levodopa dosage was increased to deal with her worsening motor symptoms.
  • She was also prescribed medication for her pain.


This article reports on an Industry Therapeutic Update (sponsored by ACADIA Pharmaceuticals Inc.) which was held at the 69th Annual American Academy of Neurology (AAN) Meeting (April 22–28, 2017) in Boston, MA, USA. The objectives of this Industry Therapeutic Update were to explore the pathophysiology, symptomology, diagnosis and impact of PDP, the role of serotonin signaling within PDP, and to examine the current standard of care for treatment for the condition. In addition, the proposed mechanism of action, efficacy, safety, and administration of pimavanserin as a treatment for hallucinations and delusions associated with PDP will be summarized.

Diagnostic issues

“PDP is far more common than many of our patients are aware; they need to know that this is part of the underlying disease.” – Stuart Isaacson

PDP can be diagnosed according to the 2007 National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) provisional diagnostic criteria.6 Diagnosis of PDP requires the presence of at least one of the following symptoms: hallucinations, illusions (i.e., misperception of actual stimuli in contrast to hallucinations which occur in the absence of real stimuli), delusions, or false sense of presence.6 Associated features that may or may not occur in PDP include insight, dementia, and the patient may or may not be receiving drugs for treatment of PD. Symptoms must occur in patients with previously diagnosed PD and must be recurrent or continuous for at least 1 month. Other causes should be excluded, including delirium, dementia with Lewy bodies, and psychiatric disorders such as schizophrenia, schizoaffective disorder, delusional disorder or mood disorders with psychotic features.6

A validated, patient self-report questionnaire (NMSQuest) was used in a study (n=242) designed to identify the non-motor symptoms – including delusions and hallucinations – that may not have been disclosed to physicians.12 Of the patients who completed the surveys and experienced symptoms, 41.5% experienced hallucinations and 65.2% experienced delusions they did not declare to their physicians. Patients may under-report PDP symptoms for a variety of reasons, including the fact that it may be unclear to patients that the non-motor symptoms they are experiencing are related to PD, and during time-restricted consultations, patients may simply not have enough time or forget to mention non-motor symptoms.12,13


Symptoms of Parkinson’s disease psychosis

  • The reason for her visit is that Rebecca – Maria’s daughter – reported that her mother has been seeing a black cat in her bedroom at night, despite having no animals in the house.
  • When asked about the cat, Maria explains that she knows the cat is not really there, but she enjoys seeing it.
  • Rebecca is disturbed by her mother’s behavior.


PDP often begins with hallucinations with retained insight13 and, while the patients remain cognizant of these PDP symptoms, they are often able to cope without behavioral disturbances.14 However, as PDP progresses, insight is often lost and delusions may occur;6,13,15 patients may find these symptoms threatening and may respond or act aggressively, creating behavioral disturbances.16 The majority of patients experiencing mild hallucinations progress to more severe symptoms;13 additionally, caregiver burden increases.17,18 In a case study review of 143 patients with PD who were admitted to a hospital, symptoms of psychosis accounted for 24% of admissions.19 Further, a 4-year prospective study carried out in Norway (n=178) identified that patients with PD experiencing hallucinations were two and a half times more likely to be admitted into a nursing home than patients with PD without hallucinations.20 In addition, mortality at 3 years was approximately 40% for patients with PD and symptoms of psychosis, based on an age-adjusted model with a baseline age of 75 years (n=230).21


Progression of Parkinson’s disease psychosis

  • On the second visit, Maria appears to be losing insight: she is now seeing the black cat more frequently and is buying cat food for it.
  • She told her daughter Rebecca to keep better control of the cat because she has almost tripped over it several times. In response, her daughter tried to explain that the cat was not real.
  • Maria is also becoming delusional, saying the nightly news anchor is talking directly to her and that Rebecca is stealing money from her.
  • Maria has been experiencing hallucinations and delusions that are potentially serious for her and disturbing to her daughter.


Both intrinsic and extrinsic factors contribute to PDP. Intrinsic factors include those associated with disease progression (older age, PD severity and duration),22 abnormalities of neurodegeneration (neurochemical abnormalities and visual processing deficits),22–24 comorbid medical conditions (e.g., urinary tract infections [UTIs]) and/or psychiatric conditions.6,22 Extrinsic factors encompass anti-Parkinson drugs (e.g., higher levodopa dose, dopamine agonists) and other medications (e.g., anticholinergics),6,22 and environmental factors (time of day and dim lighting).6,25,26

Pathophysiology of Parkinson’s disease psychosis

Emerging evidence – albeit from very small studies – indicates that psychosis can result from overactivation of both dopaminergic and serotonergic signaling.1,23,27–29 In an imaging study of five patients with PD and eight control subjects, the patients with PD showed reduced serotonin transporter binding, with the greatest reductions in the forebrain.28 A pilot study was conducted using the selective serotonin 2A receptor (5-HT2A) ligand [18F]-setoperone during positron emission tomography of seven patients with PD and visual hallucinations, and seven age-matched patients with PD but not visual hallucinations.23 Patients with PD and hallucinations were found to have increased 5-HT2A receptor binding in several regions of the brain, including the ventral visual pathway.23 In addition, results from the Parkinson’s Progression Markers Initiative showed that patients (n=21) with early onset formed hallucinations had reduced baseline higher visual function and cortical thinning in the parietal, occipital and frontal cortex, as well as reduced hippocampal volume, compared with the overall PD cohort.30 A challenge for clinicians treating patients for PD is that dopaminergic therapies for motor symptoms typically worsen psychosis,22 but the reduction of anti-Parkinson medication to treat PDP can worsen motor symptoms.31,32

“These studies provide an evidence base that, by modulating serotonin, we might be able to improve the psychotic symptoms of hallucinations and delusions in PD. It is important to consider this new way of thinking about the genesis of PDP because it opens the door to a way of treating PDP without worsening motor symptoms.”– Stuart Isaacson

Treating Parkinson’s disease psychosis

“It’s a real paradigm shift in that we finally have an FDA-approved medication to treat PDP that does not worsen motor symptoms…” – Daniel Kremens

Pimavanserin (NUPLAZID®; ACADIA Pharmaceuticals Inc., San Diego, CA, USA) – which is an atypical antipsychotic – does not worsen motor symptoms, and is the first and only Food and Drug Administration (FDA)-approved treatment for hallucinations and delusions associated with PDP.33 As with all drugs in this class, pimavanserin has a boxed warning regarding mortality in elderly patients with dementia-related psychosis.33

In vivo, pimavanserin binds to 5-HT2A receptors with a five-fold higher selectivity over 5-HT2C receptors. It has no appreciable affinity to dopaminergic receptors (including D2) or to muscarinic, histaminergic, or adrenergic receptors.33 Pimavanserin’s mechanism of action in the treatment of hallucinations and delusions associated with PDP is unknown although it may be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors, and to a lesser extent, at serotonin 5-HT2C receptors.33


Treatment of Parkinson’s disease psychosis

  • Maria’s neurologist prescribed her 34 mg of pimavanserin to treat the hallucinations and delusions she is experiencing.
  • Her neurologist reminded her and Rebecca that it is important to take pimavanserin each day and the hallucinations may begin to decrease from baseline as early as 2 weeks, though it may take up to 6 weeks to see the full benefits.


Pimavanserin pivotal phase 3 clinical study

A placebo-controlled, randomized, parallel-group study of 199 patients with PDP was conducted to determine whether pimavanserin can reduce hallucinations and delusions associated with PDP effectively.34 Eligible participants entered a 2-week nonpharmacological lead-in phase, in which patients received brief psychological therapy adapted for PD. Subsequently, patients were randomly allocated (1:1) to receive pimavanserin 34 mg per day or matched placebo for 6 weeks. The primary outcome was antipsychotic benefit as assessed by central, independent raters with the Parkinson’s disease-adapted scale for assessment of positive symptoms (SAPS-PD). The SAPS-PD is a nine-item scale, rated from 0 to 5, that includes hallucinations (five items) and delusions (four items) (Figure 2).9 A 2.33-point change on the SAPS-PD is associated with a 1.00-point change on the Clinical Global Impression-Improvement scale (CGI-I)9 indicating that a 3.00-point improvement on the SAPS-PD can mean the difference between daily and occasional symptoms of psychosis.35 The secondary endpoint was change in the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II + III.33,34

Key inclusion criteria were: age ≥40 years; PD diagnosis ≥1 year; psychotic symptoms occurred following PD onset, ≥1 month’s duration, occurred at least weekly in the month before screening, and were frequent and severe enough to warrant treatment; stable on PD medication for at least 30 days prior to study start and throughout the 6-week study; neuropsychiatric inventory ≥6 or a score of ≥4 on either the Hallucinations or Delusions domain (at screening); and ≥3 on the SAPS-hallucination or -delusions global item and ≥3 on at least one other non-global item on the SAPS-PD (at baseline).33,34 Patients with delirium or a mini-mental status exam (MMSE36) <21 points were excluded.33,34 Other exclusion criteria were psychosis secondary to toxic or metabolic disorder, psychosis following ablative stereotaxic surgery, presence of dementia concurrent or before PD, and uncontrolled serious medical illness.33,34 In addition, antipsychotic drugs, centrally acting anticholinergics, or drugs that cause QT prolongation were prohibited.33,34


Pimavanserin effectively diminished symptoms of hallucinations and delusions associated with PDP at 6 weeks (Figure 3).33,34 The mean SAPS-PD baseline score for pimavanserin 34 mg was 15.9 and 14.7 for placebo.33,34 For the primary endpoint, the point reduction on the SAPS-PD was -5.79 pimavanserin 34 mg and -2.73 placebo (p=0.0014).33,34 Patients who received pimavanserin had a mean change that resulted in a 37% improvement from baseline compared with 14% for placebo.34 The positive effect of pimavanserin on SAPS-PD improved as early as 2 weeks from baseline after starting treatment, with statistical significance seen at 4 and 6 weeks.34 In an exploratory analysis, pimavanserin also reduced the individual hallucination and delusion domain scores of the SAPS-PD compared with placebo.33 In total, 14 patients discontinued treatment after randomization but prior to the first visit post-baseline, resulting in a primary efficacy analysis population of 185. The mean age was 72.4 years for both pimavanserin 34 mg (n=95) and placebo (n=90).34

Approximately 65% of patients receiving pimavanserin experienced at least a 3-point reduction in hallucinations and delusions associated with PDP as measured by the total SAPS-PD score.33 Illustrated in the case study of Maria (described previously), these improvements can be understood in terms of Maria being unsure whether or not she sees a black cat, and seeing a cat every day and buying food for it. Further, nearly 14% of patients taking pimavanserin experienced a complete response in hallucinations and delusions associated with PDP versus just 1% of patients taking placebo.33 The change from baseline in UPDRS Parts II + III was similar between the pimavanserin 34 mg (n=92) and placebo groups (n=88; -1.4 and -1.7 respectively), indicating that there was no motor worsening associated with treatment.33

Overall, pimavanserin was well tolerated in the 6-week placebo-controlled trials, with the most common adverse events being peripheral edema and confused state (see full adverse events in Table 1). A total of 8% (16/202) of pimavanserin 34 mg-treated patients and 4% (10/231) of placebo-treated patients discontinued because of adverse reactions. The adverse reactions that occurred in more than one patient and with an incidence at least twice that of placebo were: hallucinations (2% pimavanserin 34 mg versus <1% placebo), UTIs (1% pimavanserin 34 mg versus <1% placebo), and fatigue (1% pimavanserin 34 mg versus 0% placebo).33

Clinical program for pimavanserin

This drug has what has been termed cumulative pharmacokinetics in that a steady state in Cmax is gradually achieved around 10–12 days. When you begin pimavanserin 34 mg/day without titration, as per label, you can reach the steady state that has been associated in the clinical trial with clinical efficacy and tolerability… In a sense, it self-titrates by gradually increasing its concentration in the plasma before reaching steady state.” – Stuart Isaacson

Across the clinical trial program, more than 1,200 people have been exposed to at least one oral dose of pimavanserin; 616 were patients with hallucinations and delusions associated with PDP.33 Additional clinical trial experience in patients with hallucinations and delusions associated with PDP is derived from two open-label, safety extension studies (n=497).33 As of April 2016, more than 300 patients have been treated for >6 months; >270 have been treated for at least 12 months; and >150 have been treated for at least 24 months.33

The clinical trial program included a pharmacokinetic study (Figure 4), which found that the half-life was 57 hours, whereas the time to reach maximum plasma concentration was 6 hours (range 4–24).33 A high-fat meal had no significant effect on rate and extent of pimavanserin exposure.33 Concomitant use with drugs known to prolong the QT interval, including Class 1A or Class 3 antiarrhythmics (i.e., quinidine, procainamide, disopyramide, amiodarone, sotalol), certain antipsychotics (i.e., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (i.e., gatifloxacin, moxifloxacin), should be avoided as they may add to the QT effects of pimavanserin and increase the risk of cardiac arrhythmia.33 CYP3A4 is the major enzyme responsible for pimavanserin metabolism and pimavanserin can interact with strong CYP3A4 inhibitors and CYP3A4 inducers. Examples of strong CYP3A4 inhibitors are: itraconazole, ketoconazole, clarithromycin, and indinavir, and strong CYP3A4 inducers include: rifampin, carbamazepine, phenytoin, and St. John’s wort.33 The recommended dose of pimavanserin is 34 mg once daily (any time of day), without titration; pimavanserin can be taken with or without food.33 However, the recommended dose of pimavanserin when co-administered with a strong CYP3A4 inhibitor is 17 mg, taken orally as one tablet once daily.33 When pimavanserin is co-administered with a strong CYP3A4 inducer, patients should be monitored for reduced efficacy and the dosage increased if required.33 Based on pharmacokinetic studies, no dosage adjustment of carbidopa/levodopa is required when administered concomitantly with pimavanserin.33

Use in elderly populations

In the 6-week, placebo-controlled studies for pimavanserin, patients up to 90 years were included;35 49% of the patients were 65–75 years old and 31% were >75 years old.33 Patients were required to be 40 years of age or more for inclusion, as well as have an MMSE score greater than 21 so that patients were able to self-report symptoms.33 In the pooled population of patients enrolled in 6-week, placebo-controlled studies (n=614), 27% had MMSE scores of 21–24 compared with 73% with scores ≥25.33 No clinically meaningful differences in safety or effectiveness were noted between the two groups.33 Thus, no dose adjustment is necessary for elderly patients.


More than 50% of patients with PD develop PDP at some point during the course of PD, and the symptoms generally worsen with time.5,13 Evidence suggests the symptoms of psychosis can be the result of excessive serotonergic activity in the raphe nuclei.1,27,29 Pimavanserin is the only FDA-approved treatment for hallucinations and delusions associated with PDP.33 Treatment with pimavanserin reduces hallucinations and delusions in patients with PDP without impacting motor function.33 The recommended dose of pimavanserin is 34 mg, once daily, without titration and without a dosage adjustment in concomitant carbidopa/levodopa.30

  1. Olanow CW, Schapira AHV, Obeso JA, Parkinson’s Disease and Other Movement Disorders. In: Kasper D, Fauci A, Hauser S, et al. (eds.), Harrison’s Principles of Internal Medicine 19e, New York, NY, USA: McGraw-Hill Education, 2015. Available at: (accessed March 16, 2018).
  2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
  3. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
  4. Parkinson’s Foundation. Understanding Parkinson's: statistics, 2018, New York, NY, USA. Available at: (accessed March 16, 2018).
  5. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996–1001.
  6. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061–8.
  7. Fénelon G, Soulas T, Zenasni F, et al. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:763–6.
  8. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289:12–7.
  9. Voss T, Bahr D, Cummings J, et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19:295–9.
  10. Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother. 2011;12:2009–24.
  11. Andreasen N, The scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City, IA, USA, 1984.
  12. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–9.
  13. Goetz CG, Fan W, Leurgans S, et al. The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol. 2006;63:713–6.
  14. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord. 2003;18:831–2.
  15. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43:2227–9.
  16. Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: ‘between a rock and a hard place.’ Int Rev Psychiatry. 2000;12:319–34.
  17. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14:866–74.
  18. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:629–34.
  19. Klein C, Prokhorov T, Miniovitz A, et al. Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm (Vienna). 2009;116:1509–12.
  20. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938–42.
  21. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: A prospective population-based long-term study. Neurology. 2010;75:1270–6.
  22. Wolters ECh. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl. 2006;71:31–7.
  23. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2a receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67:416–21.
  24. Holroyd S, Currie L, Wooten G. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70:734–8.
  25. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265–8.
  26. Fénelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733–45.
  27. Sadzot B, Baraban JM, Glennon RA, et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacacology (Berl). 1989;98:495–9.
  28. Albin RL, Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson’s disease. J Cereb Blood Flow Metab. 2008;28:441–4.
  29. Joutsa J, Johansson J, Seppänen M, et al. Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. J Nucl Med. 2015;56:1036–41.
  30. Ffytche DH, Pereira JB, Ballard C, et al. Risk factors for early psychosis in PD: insights from the Parkinson’s Progression Markers Initiative. J Neurol Neurosurg Psychiatry. 2017;88:325–31.
  31. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491–8.
  32. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:281.
  33. ACADIA Pharmaceuticals Inc. NUPLAZID Prescribing Information. 2017. Available at: (accessed March 12, 2018).
  34. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–40.
  35. ACADIA Pharmaceuticals Inc., San Diego, CA, US. Data on file, 2014.
  36. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Keywords: Parkinson’s disease psychosis (PDP), hallucinations, delusions, pimavanserin, diagnosis, treatment